Disc Medicine's (IRON) Outperform Rating Reiterated at Wedbush

Wedbush restated their outperform rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a research report released on Monday morning, RTT News reports. The brokerage currently has a $43.00 target price on the stock, down from their prior target price of $84.00. Wedbush also issued estimates for Disc Medicine’s Q4 2024 earnings at […]

Related Keywords

United States ,America ,Kevin Bitterman ,Raymond James ,Ameritas Investment Partners Inc ,Venture Fund Xlp Atlas ,America Corp ,Disc Medicine Inc ,Cantor Fitzgerald ,Steward Partners Investment Advisory ,Disc Medicine Company Profile ,Securities Exchange Commission ,Morgan Stanley ,Disc Medicine ,Free Report ,Moderate Buy ,Medicine Trading Down ,Get Free Report ,Director Kevin Bitterman ,Exchange Commission ,Venture Fund ,Investment Partners ,Partners Investment Advisory ,Disc Medicine Daily ,Nasdaq Iron ,Iron ,Medical ,Reiterated Rating ,Wedbush ,